Thalidomide Lipomed (Thalidomide) 100 mg
Immunomodulatory agent for multiple myeloma
Quick Facts: Thalidomide Lipomed
Key Takeaways
- Pregnancy prevention is mandatory: Thalidomide causes severe birth defects. A strict pregnancy prevention programme including effective contraception and regular pregnancy tests must be followed by all patients of childbearing potential
- Used as first-line combination therapy: Given together with melphalan and prednisone (MPT regimen) for newly diagnosed multiple myeloma in patients aged 65 or older, or in younger patients who cannot receive high-dose chemotherapy
- Monitor for peripheral neuropathy: Nerve damage in the hands and feet is a very common side effect that may be irreversible. Report tingling, numbness, or burning pain to your doctor immediately
- Increased blood clot risk: Thalidomide raises the risk of deep vein thrombosis (DVT) and pulmonary embolism. Preventive anticoagulation such as low-dose aspirin or low-molecular-weight heparin may be prescribed
- Take at bedtime: The 100 mg tablet causes marked drowsiness, so it should be taken as a single dose at bedtime with water to minimise daytime sleepiness
What Is Thalidomide Lipomed and What Is It Used For?
Thalidomide Lipomed 100 mg is a prescription immunomodulatory medicine used in combination with melphalan and prednisone to treat newly diagnosed multiple myeloma in adults aged 65 or older, or in younger adults who cannot receive high-dose chemotherapy with autologous stem cell transplantation. In specialist settings, it is also used for erythema nodosum leprosum (ENL) and certain refractory inflammatory and haematologic conditions.
Thalidomide Lipomed contains the active substance thalidomide, a medicine belonging to the class known as immunomodulatory drugs (IMiDs). Originally developed in the 1950s as a sedative and marketed as a treatment for morning sickness, thalidomide was withdrawn from the market in the early 1960s after it was discovered to cause devastating birth defects in thousands of children. Decades later, researchers identified that thalidomide had potent anti-cancer, anti-inflammatory, and immunomodulatory properties, leading to its carefully controlled reintroduction for the treatment of multiple myeloma and a small number of other conditions.
Multiple myeloma is a cancer of the plasma cells, a type of white blood cell produced in the bone marrow that normally makes antibodies. In myeloma, abnormal plasma cells multiply uncontrollably in the bone marrow, crowding out healthy blood cells and releasing large amounts of an abnormal antibody protein (paraprotein or M-protein). This process can damage bones, cause anaemia, impair kidney function, and weaken the immune system. Although multiple myeloma is generally considered incurable with current therapies, modern combination treatments can significantly prolong survival and induce long periods of disease control (remission).
Thalidomide exerts its anti-myeloma effect through several complementary mechanisms. It inhibits the formation of new blood vessels (anti-angiogenesis) that supply nutrients to tumour cells, directly induces programmed cell death (apoptosis) in myeloma cells, enhances the activity of the patient's own immune system – particularly T cells and natural killer (NK) cells – and modulates the bone marrow microenvironment by reducing levels of tumour necrosis factor alpha (TNF-α) and other pro-inflammatory cytokines that support myeloma cell survival. More recently, thalidomide has been shown to bind to the cereblon (CRBN) component of a cellular E3 ubiquitin ligase complex, promoting the degradation of transcription factors that myeloma cells depend on.
The combination of thalidomide with melphalan (a chemotherapy drug) and prednisone (a corticosteroid) is known as the MPT regimen. Multiple randomised controlled trials – including the IFM 99-06 and IFM 01-01 trials – have demonstrated that MPT significantly improves response rates, progression-free survival, and overall survival compared with melphalan and prednisone alone in elderly patients with newly diagnosed multiple myeloma. These data underpin the current international consensus that a thalidomide-containing regimen is an appropriate first-line option in patients who are not candidates for autologous stem cell transplantation.
How Thalidomide Lipomed Works
- Anti-angiogenesis: Prevents the formation of new blood vessels that supply nutrients to myeloma tumours
- Direct anti-tumour effect: Induces apoptosis (programmed cell death) in myeloma cells
- Immune stimulation: Enhances T-cell and natural killer cell activity against cancer cells
- Microenvironment modulation: Reduces TNF-α and other pro-inflammatory cytokines in the bone marrow
- Cereblon-dependent protein degradation: Binds cereblon and promotes degradation of transcription factors (IKZF1, IKZF3) that myeloma cells depend on for survival
Approved and Specialist Indications
The principal approved indication for Thalidomide Lipomed is newly diagnosed multiple myeloma in combination with melphalan and prednisone. In some countries and specialist centres, thalidomide is also used under tightly controlled conditions for:
- Erythema nodosum leprosum (ENL): A painful inflammatory complication of leprosy, for which thalidomide has been used historically and remains on the WHO Model List of Essential Medicines
- Behcet's disease: Severe mucocutaneous ulceration not responding to standard treatment
- Graft-versus-host disease (GVHD): Chronic GVHD after allogeneic stem cell transplantation, when other treatments are ineffective
- Certain refractory cutaneous conditions: Such as discoid lupus erythematosus, actinic prurigo, or aphthous ulceration in HIV
These specialist uses are generally off-label in many jurisdictions and must only be initiated and supervised by a physician experienced in the use of thalidomide.
What Should You Know Before Taking Thalidomide Lipomed?
Before starting Thalidomide Lipomed, it is essential to understand the pregnancy prevention requirements, the risk of blood clots, and the potential for nerve damage. This medicine must never be taken during pregnancy because it causes severe birth defects and fetal death. Patients must also avoid donating blood during treatment and for 7 days after the last dose.
Contraindications
You must not take Thalidomide Lipomed if any of the following apply to you:
- Pregnancy: If you are pregnant, suspect you may be pregnant, or are planning to become pregnant. Thalidomide causes severe birth defects and fetal death
- Breastfeeding: Thalidomide may pass into breast milk, and breastfeeding must be stopped before treatment
- Women of childbearing potential without contraception: If you are of childbearing potential and not following the mandatory pregnancy prevention programme with effective contraception
- Men unable to follow contraceptive requirements: Male patients who cannot or will not use condoms with their partners during and for 7 days after treatment
- Allergy: If you are allergic to thalidomide or any of the other ingredients in the tablet
Even a single 100 mg tablet of thalidomide taken during pregnancy can cause serious birth defects. These may include shortened arms or legs (phocomelia), malformed hands or feet, eye and ear defects, cleft palate, and damage to internal organs including the heart, kidneys, and gastrointestinal tract. Thalidomide must never be taken during pregnancy, and both male and female patients must follow strict contraceptive measures as described below.
Pregnancy Prevention Programme
Due to thalidomide's severe teratogenic effects, all patients must adhere to a comprehensive pregnancy prevention programme. This programme is a legal and medical requirement in all countries where thalidomide is authorised, including under the European Medicines Agency (EMA) Risk Management Plan and the United States REMS (Risk Evaluation and Mitigation Strategies) framework.
For women of childbearing potential:
- A medically supervised pregnancy test must be performed within 3 days before the start of treatment, every 4 weeks during treatment, and 4 weeks after stopping
- At least one highly effective method of contraception (intrauterine device, tubal occlusion, progestogen-only injectable, or a levonorgestrel-releasing IUS) must be used for at least 4 weeks before starting treatment, throughout the entire treatment period, and for at least 4 weeks after stopping
- Your doctor will confirm at each prescription visit that all necessary precautions have been taken before new tablets are supplied
- The prescription is limited to a maximum of 4 weeks of treatment at a time
- If you miss a menstrual period, experience unexpected vaginal bleeding, or suspect you may be pregnant, you must stop taking thalidomide immediately and inform your doctor
- Combined oral contraceptive pills are not recommended because of interactions with thalidomide and increased risk of venous thromboembolism
For men taking thalidomide:
- Thalidomide is present in semen. You must always use a condom during sexual contact throughout treatment and for at least 7 days after the last dose, even if you have had a vasectomy
- You must not donate sperm during treatment or for at least 7 days after stopping
- If your female partner becomes pregnant while you are taking thalidomide, inform your doctor immediately so that the pregnancy can be appropriately monitored and reported
Thalidomide is one of the most potent human teratogens ever identified. The critical window of vulnerability in humans is between days 20 and 36 after conception – often before a woman knows she is pregnant. The drug disrupts the growth of new blood vessels in the developing embryo, particularly affecting the limbs, ears, eyes, heart, and gastrointestinal tract. No safe dose or exposure during this window has ever been established.
Warnings and Precautions
Talk to your doctor, pharmacist, or nurse before taking Thalidomide Lipomed if any of the following apply to you:
- History of blood clots: If you have had a heart attack, deep vein thrombosis, pulmonary embolism, stroke, or if you smoke, have high blood pressure, diabetes, or high cholesterol. Thalidomide significantly increases the risk of venous and arterial thromboembolism, particularly in the first 3 to 5 months of treatment
- Peripheral neuropathy: If you have or have had nerve damage causing tingling, abnormal coordination, numbness, or pain in hands or feet. This is a very common and potentially irreversible side effect of thalidomide
- Heart conditions: If you have slow heartbeat (bradycardia), heart failure, or pre-existing arrhythmia
- Pulmonary hypertension: If you have high blood pressure in the lung arteries, as thalidomide has been associated with rare cases of pulmonary arterial hypertension
- Low blood counts: If you have reduced white blood cells (neutropenia), particularly with fever and infection, or low platelets (thrombocytopenia)
- Liver or kidney problems: Including abnormal liver function tests, hepatitis, or reduced renal function
- Severe skin reactions: If you have previously experienced Stevens-Johnson syndrome, toxic epidermal necrolysis, or DRESS syndrome (drug reaction with eosinophilia and systemic symptoms)
- Viral infections: Particularly varicella zoster, hepatitis B, hepatitis C, or HIV. Thalidomide can reactivate latent viral infections, including causing shingles (herpes zoster) and hepatitis B reactivation
- Tumour lysis syndrome: Patients with high tumour burden may experience dangerous metabolic changes at the start of treatment as myeloma cells break down rapidly
- Thyroid disorders: Thalidomide can cause hypothyroidism; thyroid function should be monitored
Tell your doctor immediately if you experience blurred vision, vision loss, double vision, difficulty speaking, weakness in an arm or leg, changes in walking or balance, persistent numbness, memory loss, or confusion. These may be signs of PML, a rare but serious brain condition caused by reactivation of the JC virus and associated with immunosuppressive therapies.
Blood donation: You must not donate blood during treatment or for at least 7 days after treatment ends. This is to avoid the possibility of a pregnant woman receiving thalidomide through a blood transfusion.
Children and adolescents: Thalidomide Lipomed is not recommended for use in children and adolescents under 18 years of age because safety and efficacy in this age group have not been sufficiently established.
Elderly patients: Patients over 75 years of age require dose reduction (see dosage section) and closer monitoring, as they are at increased risk of thromboembolism, infections, peripheral neuropathy, and haematological toxicity.
Pregnancy and Breastfeeding
Thalidomide is one of the most well-documented human teratogens. The thalidomide tragedy of the late 1950s and early 1960s resulted in severe birth defects in an estimated 10 000 children worldwide, leading to its withdrawal from most markets and fundamentally changing drug safety regulations and the practice of pharmacovigilance globally. Survivors of this era continue to experience long-term physical and social consequences.
If a patient becomes pregnant while taking thalidomide, the medicine must be stopped immediately and the treating doctor must be informed. The patient should be referred to a physician specialising in teratology for evaluation and counselling. The case should also be reported to the relevant national pharmacovigilance authority.
Breastfeeding: You must not breastfeed while taking Thalidomide Lipomed. It is not known with certainty whether thalidomide passes into human breast milk, but because of the potential for serious harm to the infant, breastfeeding is contraindicated during treatment and should remain so for at least 7 days after the last dose.
Driving and operating machinery: Thalidomide very commonly causes dizziness, fatigue, drowsiness, and blurred vision, particularly at the start of treatment and after dose increases. Do not drive, operate heavy machinery, or engage in activities requiring alertness if you experience any of these effects. Many patients find the sedative effect most pronounced in the hours after taking the tablet, which is one reason dosing is recommended at bedtime.
How Does Thalidomide Lipomed Interact with Other Drugs?
Thalidomide interacts with several drug classes, most importantly sedatives, anticoagulants, hormonal contraceptives, and medicines that cause bradycardia or peripheral neuropathy. Alcohol should be avoided as it potentiates thalidomide's sedative effects. Always inform your doctor about all medicines, supplements, and herbal products you are taking.
Thalidomide can interact with a wide range of medications, either by enhancing their effects, by increasing the risk of specific side effects, or by altering its own metabolism. Although thalidomide is predominantly metabolised by non-enzymatic hydrolysis rather than by CYP450 enzymes, clinically significant pharmacodynamic interactions are common. It is essential to tell your doctor and pharmacist about all medicines you take, including over-the-counter products, herbal remedies, and dietary supplements.
| Drug / Class | Interaction | Clinical Significance |
|---|---|---|
| Sedatives, anxiolytics, hypnotics (e.g. benzodiazepines, barbiturates, Z-drugs) | Enhanced sedation and CNS depression | Major – avoid or use with extreme caution |
| Opioid analgesics (e.g. morphine, oxycodone) | Increased drowsiness and respiratory depression risk | Major – dose adjustment may be required |
| Antihistamines (first-generation H1 blockers) | Enhanced sedative and anticholinergic effects | Moderate – monitor for excessive drowsiness |
| Beta-blockers, anticholinesterases | Additive bradycardia (slow heart rate) | Moderate – monitor heart rate and ECG |
| Digoxin | Additive cardiac effects, possible increased digoxin levels | Moderate – monitor ECG and digoxin levels |
| Warfarin and other oral anticoagulants | Altered coagulation parameters | Moderate – monitor INR closely |
| Hormonal contraceptives | Possible reduced contraceptive efficacy; increased VTE risk with combined pill | Major – combined oral contraceptives not recommended; use IUD/IUS or additional barrier method |
| Dexamethasone and high-dose corticosteroids | Markedly increased risk of venous thromboembolism | Major – thromboprophylaxis (e.g. aspirin or LMWH) is usually required |
| Other neurotoxic drugs (e.g. vincristine, bortezomib, cisplatin) | Additive peripheral neuropathy risk | Major – avoid combination when possible, monitor neurological status closely |
| Erythropoiesis-stimulating agents (e.g. epoetin, darbepoetin) | Possible increased thrombotic risk | Moderate – weigh benefits against risks, consider thromboprophylaxis |
| Alcohol | Potentiated sedation and CNS depression | Major – avoid alcohol completely |
| Grapefruit juice | Limited data, but some authorities recommend caution | Minor – no strict prohibition, but moderation advised |
Major Interactions
The most clinically significant interactions involve medicines that cause sedation or central nervous system depression. Thalidomide itself is a potent sedative, and combining it with benzodiazepines, opioids, barbiturates, first-generation antihistamines, antipsychotics, or alcohol can lead to profound CNS depression, impaired breathing, falls, and accidents. Patients and carers should be warned about the additive sedative effects and advised not to drive or operate machinery when these combinations are used.
Hormonal contraceptives require special consideration. Combined oral contraceptives (containing oestrogen) are not recommended alongside thalidomide because they independently increase the risk of venous thromboembolism, which is already elevated by thalidomide. In addition, some data suggest that thalidomide may reduce the efficacy of hormonal contraceptives. Recommended highly effective alternatives include the copper intrauterine device, levonorgestrel-releasing intrauterine system, progestogen-only injectable contraceptive, or tubal occlusion.
The combination of thalidomide with dexamethasone or other high-dose corticosteroids is particularly thrombogenic. Patients on such regimens almost always require prophylactic anticoagulation – commonly low-dose aspirin for patients at standard risk, or low-molecular-weight heparin (LMWH) or oral anticoagulants for patients at higher risk.
Moderate Interactions
Medicines that slow the heart rate – such as beta-blockers, acetylcholinesterase inhibitors (used in Alzheimer's disease), and non-dihydropyridine calcium channel blockers – can have additive effects with thalidomide, potentially causing clinically significant bradycardia or heart block. Heart rate and ECG should be monitored in patients receiving these combinations. Similarly, patients on anticoagulants such as warfarin should have their INR monitored more frequently, as thalidomide may alter coagulation parameters and the underlying disease (multiple myeloma) itself affects coagulation balance.
Minor Interactions
The interaction between thalidomide and grapefruit juice is not fully characterised; thalidomide is not primarily metabolised via CYP3A4, so major pharmacokinetic interactions are unlikely. Nevertheless, some product information recommends moderating grapefruit intake during treatment. No clinically significant interaction has been established with food in general, and Thalidomide Lipomed can be taken with or without food.
What Is the Correct Dosage of Thalidomide Lipomed?
In multiple myeloma, the standard dose of Thalidomide Lipomed is 200 mg (two 100 mg tablets) once daily for adults under 75 years, and 100 mg (one 100 mg tablet) once daily for adults aged 75 years or older. The dose is taken as a single bedtime dose in 6-week treatment cycles alongside melphalan and prednisone. Doses may be reduced further for tolerability.
Always take Thalidomide Lipomed exactly as your doctor or pharmacist has told you. The dose and duration of treatment will be tailored to your individual needs, including your age, body weight, renal and hepatic function, blood counts, and tolerance of the medicine. If you are unsure, check with your treating haematologist or oncology nurse.
| Patient Group | Recommended Dose | Special Instructions |
|---|---|---|
| Adults under 75 years | 200 mg (2 × 100 mg tablets) once daily | Take at bedtime as single dose |
| Adults 75 years and over | 100 mg (1 × 100 mg tablet) once daily | Take at bedtime as single dose |
| Dose reduction for toxicity | Reduce to 100 mg, 50 mg, or stop | Guided by neuropathy grade, blood counts, and VTE events |
| Renal impairment | No specific dose adjustment required | Monitor closely; thalidomide is mainly eliminated by non-renal routes |
| Hepatic impairment | No specific dose adjustment required | Limited data; use cautiously and monitor liver function |
| Children and adolescents <18 years | Not recommended | Safety and efficacy not established under 18 years |
Adults
Standard adult dose (under 75 years)
Two 100 mg tablets (200 mg total) once daily at bedtime, taken continuously throughout each 6-week cycle of the MPT regimen. Treatment is continued for up to 12 cycles, or until disease progression or unacceptable toxicity. Dose reductions to 100 mg or 50 mg daily are common if peripheral neuropathy, thromboembolism, or haematological toxicity develops.
Elderly (75 years and over)
Starting dose for patients aged 75+
One 100 mg tablet once daily at bedtime. The reduced starting dose reflects the higher risk of adverse effects in elderly patients, including deep vein thrombosis, peripheral neuropathy, infections, and falls. Further reductions are guided by tolerance. Close monitoring of blood pressure, heart rate, blood counts, and neurological status is essential.
Children and Adolescents
Under 18 years
Thalidomide Lipomed is not recommended in children or adolescents under 18 years of age because safety and efficacy in this age group have not been adequately established. Use in paediatric patients should be restricted to specialist centres within the context of clinical trials or named-patient programmes.
Treatment Cycles
In multiple myeloma, Thalidomide Lipomed is taken every day as part of a 6-week treatment cycle. Within each cycle, melphalan and prednisone are administered on days 1 through 4, while thalidomide is taken continuously every day throughout the full 6-week period. Your haematologist will determine how many treatment cycles you need based on your response to therapy, measured by blood tests (including paraprotein and free light chains), bone marrow assessment where appropriate, and imaging. Most patients receive up to 12 cycles of MPT.
How to Take the Tablets
- Swallow the coated tablets whole with a full glass of water
- Do not crush, break, split, or chew the tablets
- Take as a single dose at bedtime to minimise daytime drowsiness and dizziness
- The tablets can be taken with or without food, but consistency from day to day is advisable
- When removing tablets from the blister pack, handle them carefully; if a tablet breaks, healthcare professionals and caregivers should wear disposable gloves
- If powder from a broken tablet contacts the skin, eyes, or mucous membranes, wash the area immediately and thoroughly with soap and water
- Pregnant women must never handle the tablets, even when intact
Missed Dose
If you forget to take Thalidomide Lipomed at the usual time:
- Less than 12 hours late: Take the missed dose immediately and continue with your normal schedule
- More than 12 hours late: Do not take the missed dose. Wait and take your next dose at the usual time the following day
Do not take a double dose to make up for a forgotten dose. If you are unsure, contact your doctor, pharmacist, or oncology nurse for advice.
Overdose
If you take more Thalidomide Lipomed than prescribed, contact your doctor or go to the nearest hospital emergency department immediately. If possible, bring the medicine packaging and the patient information leaflet with you. Symptoms of overdose may include severe drowsiness, lethargy, confusion, respiratory depression, and loss of consciousness. There is no specific antidote; treatment is supportive and may include activated charcoal if presentation is early, cardiorespiratory monitoring, and symptomatic care.
What Are the Side Effects of Thalidomide Lipomed?
The most common side effects of Thalidomide Lipomed include peripheral neuropathy (nerve damage), constipation, drowsiness, dizziness, tremor, and low blood cell counts. Serious side effects include blood clots (DVT, pulmonary embolism), severe skin reactions, hepatic impairment, and an increased risk of secondary cancers. Report any new or worsening symptoms to your doctor promptly.
Like all medicines, Thalidomide Lipomed can cause side effects, although not everybody gets them. Some side effects can be serious and may require immediate medical attention. Your healthcare team will monitor you closely during treatment with scheduled blood tests, neurological examinations, and symptom reviews.
- Severe skin reactions: rash with or without blisters, sores in mouth/throat/eyes/genitals, widespread skin peeling, fever, or flu-like symptoms (signs of Stevens-Johnson syndrome, toxic epidermal necrolysis, or DRESS syndrome)
- Severe allergic reactions: widespread hives, swelling of face/mouth/eyes/tongue, difficulty breathing, wheezing, or chest tightness (anaphylaxis or angioedema)
- Signs of a blood clot: sudden chest pain, breathlessness, haemoptysis, leg swelling or pain, facial droop, slurred speech, or weakness on one side of the body
- Signs of severe infection with low white blood cells: high fever, chills, rigors, severe sore throat, or persistent cough
Very Common
Affects more than 1 in 10 patients
- Peripheral neuropathy (tingling, numbness, pain in hands/feet)
- Constipation
- Dizziness
- Drowsiness, sedation, or fatigue
- Tremor (shaking)
- Dysaesthesia (abnormal or reduced sensation)
- Peripheral oedema (swelling in hands and feet)
- Low blood cell counts: anaemia, neutropenia, thrombocytopenia
- Headache
Common
Affects up to 1 in 10 patients
- Deep vein thrombosis (DVT) and pulmonary embolism (blood clots)
- Digestive problems: nausea, vomiting, dry mouth, dyspepsia (indigestion)
- Rash, dry skin, itching
- Febrile neutropenia (low white cells with fever)
- Pancytopenia (low red cells, white cells, and platelets)
- Weakness, faintness, orthostatic low blood pressure
- Seizures
- Blurred vision
- Pneumonia and other lung infections
- Slow heart rate (bradycardia), heart failure
- Depression, confusion, mood changes, anxiety
- Hearing loss or deafness
- Renal impairment
- Weight gain or weight loss
Uncommon
Affects up to 1 in 100 patients
- Bronchitis (inflammation of airways)
- Gastritis (inflammation of stomach lining)
- Intestinal perforation (hole in the colon), which can cause infection
- Intestinal obstruction
- Severe orthostatic hypotension (blood pressure drop on standing, may cause fainting)
- Cardiac arrhythmias (heart block or atrial fibrillation)
- Myocardial infarction (heart attack)
- Cerebrovascular accident (stroke)
Rare / Frequency Not Known
Rare or cannot be estimated from available data
- Hypothyroidism (underactive thyroid)
- Sexual dysfunction (including erectile dysfunction)
- Severe sepsis and septic shock
- Tumour lysis syndrome (dangerous metabolic disturbance from rapid tumour breakdown)
- Liver damage and abnormal liver function tests
- Gastrointestinal bleeding
- Worsening of Parkinson's disease symptoms
- Pancreatitis (inflammation of the pancreas)
- Pulmonary arterial hypertension
- Viral reactivation: herpes zoster (shingles), hepatitis B, cytomegalovirus
- Posterior reversible encephalopathy syndrome (PRES)
- Leukocytoclastic vasculitis (inflammation of small blood vessels in the skin)
- Progressive multifocal leukoencephalopathy (PML)
- Second primary malignancies, including acute myeloid leukaemia (AML) and myelodysplastic syndrome (MDS)
A small proportion of patients with multiple myeloma may develop other cancers during or after treatment, particularly haematological malignancies such as acute myeloid leukaemia and myelodysplastic syndromes, and (less commonly) solid tumours. Combination therapy with thalidomide, melphalan, and other agents may contribute to this risk. Your haematologist will carefully weigh the benefits of thalidomide-based therapy against this risk and continue surveillance after treatment.
Peripheral Neuropathy – Important Information
Peripheral neuropathy is one of the most clinically significant side effects of thalidomide. It typically manifests as tingling (paraesthesia), numbness, burning sensations, aching pain, or abnormal coordination in the hands and feet, usually in a glove-and-stocking distribution. Some patients also experience reduced reflexes or mild muscle weakness. The neuropathy is predominantly sensory and appears to be dose-dependent and cumulative.
Neuropathy may develop after several months of treatment, but it can occur earlier, particularly at higher cumulative doses or when thalidomide is combined with other neurotoxic drugs such as bortezomib or vincristine. If you experience any symptoms of neuropathy, inform your doctor immediately. They may reduce your dose, temporarily stop treatment, or discontinue thalidomide permanently. In some cases, the neuropathy may not fully resolve even after stopping the drug; symptoms may persist or improve only slowly over months or years. Early detection and prompt dose modification are key to preventing permanent disabling damage.
Blood Clots – Venous Thromboembolism
Thalidomide, particularly when combined with dexamethasone, doxorubicin, or other chemotherapy agents, significantly increases the risk of venous thromboembolism (VTE), including deep vein thrombosis and pulmonary embolism. Arterial events (heart attack, stroke) are also more frequent. Warning signs include:
- Deep vein thrombosis (DVT): Pain, tenderness, warmth, redness, or swelling in the legs, especially the lower leg or calf, usually on one side
- Pulmonary embolism: Sudden shortness of breath, sharp chest pain worse on breathing in, coughing up blood, rapid heartbeat, or light-headedness
- Heart attack: Crushing chest pain spreading to arms, neck, jaw, or back, with sweating, nausea, and breathlessness
- Stroke: Sudden face droop, weakness on one side of the body, slurred speech, vision loss, or severe headache
Seek emergency medical help immediately if you experience any of these symptoms. Your haematologist will usually prescribe preventive anticoagulation (such as low-dose aspirin for standard-risk patients, or low-molecular-weight heparin for higher-risk patients) throughout thalidomide treatment.
How Should You Store Thalidomide Lipomed?
Store Thalidomide Lipomed out of the sight and reach of children at all times. No special storage conditions are required; tablets can be kept at room temperature below 25°C. Do not use the medicine after the expiry date on the packaging. Return all unused tablets to a pharmacy after treatment ends.
Keep this medicine out of the sight and reach of children at all times. This is particularly important for thalidomide because of its teratogenic properties; accidental ingestion by a child or adult, particularly a pregnant woman, could have severe consequences.
- Do not use this medicine after the expiry date (EXP) printed on the carton and blister pack. The expiry date refers to the last day of that month
- Store at room temperature below 25°C, in the original packaging to protect the tablets from light and moisture
- Do not refrigerate or freeze
- Do not remove tablets from the blister pack until you are ready to take them
- Do not use the medicine if you notice any damage to the packaging or signs of tampering
- Unused or expired tablets must be returned to a pharmacy or to your treating doctor after treatment ends. Do not throw the tablets away via household waste or wastewater. These measures prevent misuse and protect others – including children, pregnant women, and the environment – from accidental exposure
What Does Thalidomide Lipomed Contain?
Each Thalidomide Lipomed coated tablet contains 100 mg of thalidomide as the active substance. The tablet is presented as a coated tablet for oral administration and is supplied in blister packs for monthly dispensing.
Active Ingredient
Each coated tablet contains 100 mg of thalidomide.
Other Ingredients
The exact list of excipients is given in the approved Patient Information Leaflet supplied with each pack. Typical excipients for Thalidomide Lipomed coated tablets include:
- Tablet core: Pregelatinised starch, microcrystalline cellulose, croscarmellose sodium, magnesium stearate, and colloidal anhydrous silica
- Tablet coating: Hypromellose, titanium dioxide (E171), macrogol, and talc; colouring agents may be added depending on the specific formulation
If you have a known allergy or intolerance to any excipient, discuss this with your doctor or pharmacist before starting treatment. Always refer to the current approved product information for the definitive list of ingredients.
Appearance and Pack Size
Thalidomide Lipomed 100 mg coated tablets are typically supplied in child-resistant blister packs within a carton suitable for 4 weeks of treatment under the pregnancy prevention programme. The exact pack size and tablet appearance (colour, markings) may vary by country and market. Always compare the tablets you receive with the description in the patient information leaflet, and contact your pharmacist if anything looks unusual.
The marketing authorisation holder is Lipomed. The product is supplied through restricted distribution programmes in participating European countries and other jurisdictions. Thalidomide Lipomed is not intended for use in countries where it has not received regulatory authorisation.
Frequently Asked Questions About Thalidomide Lipomed
Thalidomide was originally marketed in the late 1950s as a sedative and morning-sickness treatment. It was withdrawn in the early 1960s after it was discovered to cause severe birth defects in thousands of children. However, research from the 1990s onwards showed that thalidomide has potent anti-cancer, anti-inflammatory, and immunomodulatory properties. It was reintroduced under extremely strict safety controls for the treatment of multiple myeloma and erythema nodosum leprosum, among other specialist indications. Today, it is only available through regulated programmes that include mandatory pregnancy prevention measures, prescriber and patient registration, and tightly controlled dispensing. Used within this framework, it provides substantial clinical benefit to carefully selected patients.
No, you should avoid alcohol while taking Thalidomide Lipomed. Both thalidomide and alcohol cause drowsiness and central nervous system depression, and combining them can lead to excessive sedation, impaired judgement, falls, and even respiratory depression. This combination also increases the risk of accidents, particularly when driving or operating machinery. If you have concerns about alcohol consumption or social situations, discuss them with your doctor or oncology nurse.
Treatment duration varies between patients and depends on your diagnosis, your response to therapy, and how well you tolerate the medicine. In newly diagnosed multiple myeloma, thalidomide is typically given in 6-week treatment cycles alongside melphalan and prednisone for up to 12 cycles (approximately 18 months). Your haematologist will regularly assess your progress through blood tests (including paraprotein and free light chain measurements), bone marrow examinations, and imaging. Some patients may have their treatment stopped earlier due to side effects such as peripheral neuropathy; others may continue longer if they are responding well and tolerating treatment.
Tingling, numbness, pain, or burning sensations in the hands or feet may be signs of peripheral neuropathy, a very common side effect of thalidomide. Contact your doctor as soon as possible if you experience these symptoms – do not wait for your next scheduled appointment. Early intervention is important because your doctor may need to reduce your dose or stop treatment to prevent the nerve damage from becoming permanent. Keep a symptom diary (where on the body, how severe, and how it changes over time) to help your clinical team monitor any progression. In some cases, supportive treatments such as vitamin supplementation or specific neuropathic pain medicines may be prescribed.
No. You must not donate blood during treatment with Thalidomide Lipomed or for at least 7 days after stopping treatment. This rule exists to prevent the possibility of a pregnant recipient being exposed to thalidomide through a transfusion. Male patients must also not donate sperm during treatment or for at least 7 days after stopping, because thalidomide passes into semen and could potentially cause harm if the semen is used for conception. Your blood service should be informed about any medicines you are taking so they can apply the correct deferral period.
No, although they are closely related. Lenalidomide (Revlimid) and pomalidomide (Imnovid / Pomalyst) are structurally related compounds known as thalidomide analogues, or second- and third-generation immunomodulatory drugs (IMiDs). They were developed to improve on thalidomide's anti-myeloma effects while potentially reducing some side effects, particularly peripheral neuropathy. However, all three drugs share the risk of teratogenicity and venous thromboembolism, and all require strict pregnancy prevention programmes. Your haematologist will choose the most appropriate immunomodulatory drug based on your specific clinical situation, prior treatments, and tolerability profile.
Yes, in most cases. Thalidomide substantially increases the risk of venous thromboembolism (VTE), especially when combined with corticosteroids such as dexamethasone or prednisone. International guidelines from groups such as the International Myeloma Working Group (IMWG) and NCCN recommend that all patients on thalidomide-based therapy receive thromboprophylaxis. The choice depends on your individual VTE risk: patients at standard risk typically receive low-dose aspirin, while those at higher risk (history of thrombosis, major surgery, obesity, immobility, inherited thrombophilia) receive low-molecular-weight heparin (LMWH) or oral anticoagulants. Your haematologist will discuss the most appropriate option for you.
Prescriptions are limited to a maximum of 4 weeks of treatment to ensure that the pregnancy prevention programme is rigorously followed. Women of childbearing potential must have a medically supervised pregnancy test every 4 weeks before a new supply is dispensed, and the prescriber must re-confirm that contraception is in place. The 4-week limit also allows for close monitoring of side effects such as neuropathy, blood counts, and signs of thromboembolism, so that dose adjustments can be made promptly if needed.
References
- European Medicines Agency (EMA). Thalidomide – Summary of Product Characteristics and Risk Management Plan. Available at: www.ema.europa.eu
- Facon T, Mary JY, Hulin C, et al. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial. The Lancet. 2007;370(9594):1209-1218.
- Hulin C, Facon T, Rodon P, et al. Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial. Journal of Clinical Oncology. 2009;27(22):3664-3670.
- National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology: Multiple Myeloma. Current version.
- Palumbo A, Rajkumar SV, Dimopoulos MA, et al. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia. 2008;22(2):414-423.
- World Health Organization. WHO Model List of Essential Medicines – 23rd List (2023). Geneva: WHO; 2023.
- NICE Technology Appraisal Guidance TA228. Thalidomide for the first-line treatment of multiple myeloma. National Institute for Health and Care Excellence.
- Vargesson N. Thalidomide-induced teratogenesis: history and mechanisms. Birth Defects Research Part C: Embryo Today. 2015;105(2):140-156.
- Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma. New England Journal of Medicine. 1999;341(21):1565-1571.
- Palumbo A, Bringhen S, Caravita T, et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. The Lancet. 2006;367(9513):825-831.
- Krift M, et al. Thalidomide and its analogues: mechanisms of action and clinical applications. British Journal of Haematology. 2020;190(6):789-804.
- Food and Drug Administration (FDA). Thalidomide Prescribing Information and REMS Programme. Available at: www.fda.gov
About the Medical Editorial Team
This article was written and reviewed by the iMedic Medical Editorial Team, comprising licensed specialist physicians in oncology, haematology, and clinical pharmacology.
Medical Review
All content undergoes rigorous review by board-certified medical specialists. Our editorial process follows international guidelines from EMA, WHO, NCCN, and NICE.
Evidence Standards
We use only evidence level 1A sources: systematic reviews, meta-analyses, and randomised controlled trials published in peer-reviewed medical journals.
Independence
iMedic receives no commercial funding from pharmaceutical companies. All content is editorially independent and free from advertising influence.
Updates
Articles are reviewed at least annually and updated whenever new evidence or guideline changes emerge. Last review: .